Loading…
Loading…
NBIO does not currently pay a dividend.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for NBIO and 80,000+ other tickers.
See exactly how NBIO's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for NBIO and 80,000+ other tickers.
Nascent Biotech, Inc., a clinical-stage biopharmaceutical firm, is committed to creating monoclonal antibody-based treatments for various forms of cancer. A primary focus is Pritumumab, a therapeutic currently in development to address aggressive brain malignancies such as glioblastoma and malignant astrocytoma. This drug also targets numerous epithelial cancers, including those affecting the lung, breast, colon, brain, and pancreas. Additionally, the company is advancing MultiPharm, its proprietary technology platform, which holds promise for applications in cancer therapy, diabetes, autoimmune disorders, and transplantation. The company's headquarters are situated in Vero Beach, Florida.
Nascent Biotech, Inc. (OTCMKTS:NBIO - Get Free Report)'s share price passed above its 50-day moving average during trading on Thursday. The stock has a 50-day moving average of $0.00 and traded as high as $0.0003. Nascent Biotech shares last traded at $0.0003, with a volume of 351,058 shares trading hands. Nascent Biotech Stock Performance
Nascent CEO-Sean Carrick-Discusses Phase I Results and Forward Clinical Strategy while laying out Investment Opportunity of the Company NORTH PALM BEACH, FL / ACCESSWIRE / July 30, 2024 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company developing monoclonal antibodies targeting various cancer types, is pleased to provide an overview of the Company's presentation at The Emerging Growth Conference on July 18, 2024. Click here to view the Company's entire presentation.
NORTH PALM BEACH, FL / ACCESSWIRE / April 16, 2024 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company developing monoclonal antibodies targeting various cancer types, announces that it is embarking on a fresh manufacturing run to ensure Pritumumab ("PTB") supplies are at maximum potency when patient dosing begins in the upcoming Phase II clinical trial. "Taking the time to navigate this opportunity with proper care and diligence is a step that demonstrates our commitment to the best interests of our investors, partners, shareholders, and potential future patients," remarked Sean Carrick, CEO of NBIO.
NORTH PALM BEACH, FL / ACCESSWIRE / March 19, 2024 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company developing monoclonal antibodies targeting various cancer types, and HypoSpray Pharma ("HypoSpray®"), a clinical and commercial stage drug delivery technology company, announced today a collaboration to develop an alternative delivery mechanism for patients who can benefit from Pritumumab ("PTB"), Nascent's lead monoclonal antibody cancer treatment asset, which is now in Phase II clinical research for the treatment of Brain Cancer. Once successfully commercialized, the Company hopes to eliminate bi-weekly weekly infusions, allowing patients to administer Pritumumab and avoid inconvenient, tedious, and uncomfortable multi hour cancer center treatment visits.
NORTH PALM BEACH, FL and NEW YORK, NY / ACCESSWIRE / February 6, 2024 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent"), a clinical-stage biotechnology company pioneering the development of monoclonal antibodies for the treatment of various cancers and viral infections, announced today it has entered into a research collaboration agreement with Manhattan BioSolutions, Inc. (Manhattan Bio), an emerging biotech company focused on precision biologics, to explore antibody-drug conjugates (ADCs) using Nascent's lead clinical candidate pritumumab (PTB) as the tumor-targeting antibody element. Pritumumab (PTB) is a natural human antibody.